Joan Meeting Room Booking Now Certified for Crestron Room Scheduling Panels
Joan, the meeting room booking system with the longest tradition, proudly announces its latest achievement: adding Crestron integration to its portfolio. This milestone confirms Joan has passed the official validation to work seamlessly with Crestron scheduling solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250128918068/en/
Now you can use Joan meeting room booking solution on Crestron schedulers. (Photo: Business Wire)
The new integration addresses a key challenge in modern workplaces: the seamless combination of display hardware and room management software. With Joan’s open platform, organizations no longer need to choose between their preferred hardware and booking software. By leveraging Crestron devices, users can access Joan’s powerful, intuitive system for managing meeting rooms and scheduling without compromising their existing infrastructure.
“We understand that organizations often grapple with the complexity of managing diverse meeting rooms with varying requirements,” said Rok Zalar, CEO of Visionect, the company behind the brand Joan Workplace. “Our goal is to provide the flexibility to integrate Joan into any environment, whether customers have long-standing devices or brand-new setups. Joan’s open platform adapts to the needs of every user, and with Crestron, we’re delivering a seamless, hassle-free experience that enhances productivity without compromising existing hardware or investments.”
Bob Bavolacco, director of technology partnerships for Crestron adds, “As more organizations are revising their real estate needs to accommodate a hybrid workforce, meeting rooms are a crucial aspect of the office providing a place for meaningful collaboration among their colleagues. Crestron room scheduling panels natively support the Joan platform to allow employees to book a room in advance or easily find an open space for impromptu meetings.”
Joan’s flexibility has been a cornerstone of its growing reputation in the workplace industry. Organizations now have the freedom to optimize their meeting room management without the limitations of rigid systems. The integration with Crestron enhances this flexibility by integrating seamless control with Crestron LED indicators, which provide clear visual status updates (e.g., green for available rooms, red for occupied rooms). This intuitive integration allows employees to interact effortlessly with Joan's room booking system on Crestron room scheduling panels, facilitating a smooth transition to a smarter workspace.
Beyond flexibility, Joan’s brand promise emphasizes the design of intuitive, user-friendly workplace solutions. From meeting room and desk booking to visitor management, every product is crafted with simplicity in mind. Joan’s proprietary e-paper meeting room schedulers exemplify this commitment. Designed for both elegance and sustainability, they feature high-contrast black-and-white displays, a three-month battery life and wireless mounting.
About Joan Workplace
Joan Workplace, a brand of Visionect, offers an open platform of workplace solutions designed to simplify office reservations and information flow. It includes solutions for meeting room, desk, and asset booking, visitor management, and workplace digital signage. As a multiple-time design award winner and G2’s #1 room booking software for 2024, Joan’s solutions are trusted by numerous Fortune 500 companies.
About Crestron
At Crestron, we build technology for every way people work everywhere in the world – from desktops to boardrooms, offices to multinationals. Technology that adapts to what you have and prepares you for what you will need. Platforms, devices, and systems designed to improve communication and collaboration, are all managed by a cloud-based system for easy deployment, monitoring, and upgrading. At Crestron, we create simpler solutions so people can work faster, better, and more productively. Discover Crestron at www.crestron.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250128918068/en/
Contacts
For Media Inquiries
Ana Krizmancic, Marketing Director
ana.krizmancic@visionect.com
+386 31 899 850
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 202531.1.2025 13:42:00 EET | Press release
Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/ Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire) The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)31.1.2025 08:00:00 EET | Press release
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown lines (glabellar lines)1. Galderma’s analysis was presented at the International Master Course on Aging Science (IMCAS) 2025 annual congress, held in Paris from January 30 to February 1, 2025. Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule3,4,5.Previously announced data from the phase III READY clinical trial program demonstrated rapid onset as soon as Day 1 (reported by up to 39% of subjects) and long-lasting efficacy for 6 months (main
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain31.1.2025 01:25:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109747971/en/ JOURNAVX bottle and tablet (Photo: Business Wire) “Today’s approval is a historic milestone for the 80 million people in America who are prescribed a medicine for moderate-to-severe acute pain each year,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “With the approval of JOURNAVX, a non-opioid, pain signal inhibitor and the first new class of pain medicine approved in more than 20 years, we h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom